Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has earned a consensus rating of “Moderate Buy” from the nine analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $23.3333.

Several analysts have recently weighed in on ZVRA shares. Weiss Ratings raised shares of Zevra Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, May 8th. BTIG Research started coverage on shares of Zevra Therapeutics in a research note on Monday, March 16th. They set a “buy” rating and a $23.00 price target for the company. Guggenheim lifted their price target on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Finally, Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, April 11th.

Zevra Therapeutics Stock Performance

Zevra Therapeutics stock opened at $11.01 on Monday. The company has a 50 day moving average price of $9.98 and a 200-day moving average price of $9.27. Zevra Therapeutics has a fifty-two week low of $7.16 and a fifty-two week high of $13.16. The company has a market capitalization of $650.91 million, a PE ratio of 5.53 and a beta of 0.88.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.12. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. The firm had revenue of $36.22 million during the quarter, compared to the consensus estimate of $31.96 million. On average, analysts forecast that Zevra Therapeutics will post 0.56 earnings per share for the current year.

Institutional Trading of Zevra Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. CWM LLC raised its stake in Zevra Therapeutics by 399.5% in the third quarter. CWM LLC now owns 2,872 shares of the company’s stock worth $27,000 after buying an additional 2,297 shares in the last quarter. Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new position in Zevra Therapeutics in the fourth quarter worth approximately $53,000. Russell Investments Group Ltd. raised its stake in Zevra Therapeutics by 235.7% in the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock worth $61,000 after buying an additional 4,475 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in Zevra Therapeutics by 617.5% in the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after buying an additional 8,552 shares in the last quarter. Finally, Creative Planning bought a new position in Zevra Therapeutics in the second quarter worth approximately $92,000. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.